1004545-97-4

Basic information

• Product Name: 2-Amino-3-hydroxybenzaldehyde
• Synonyms: 2-Amino-3-hydroxybenzaldehyde;Benzaldehyde, 2-amino-3-hydroxy-
• CAS NO: 1004545-97-4
• Molecular Formula: C₇H₇NO₂
• Molecular Weight: 137.13598
• Mol File: 1004545-97-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-Amino-3-hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-3-hydroxybenzaldehyde(1004545-97-4)
• EPA Substance Registry System: 2-Amino-3-hydroxybenzaldehyde(1004545-97-4)

Safety Data

• Hazardous Substances Data: 1004545-97-4(Hazardous Substances Data)

Usage

Derivative of

Benzaldehyde

Functional groups

Amino group (-NH2), Hydroxyl group (-OH)

Common uses

Intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds

Biological and pharmacological activities

Antioxidant, antimicrobial

Potential therapeutic applications

Studied for the development of new drugs for various medical conditions

Valuable building block

Due to its chemical structure and properties, it serves as a valuable building block for the synthesis of biologically active compounds.

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 42123-33-1 3-hydroxy-2-nitrobenzaldehyde 

Downstream Products

• 1004545-76-9 2-amino-3-(1-hydroxybut-3-enyl)phenol 
• 6961-25-7 2-phenyl-8-hydroxy-quinoline 
• 457948-81-1 C₁₆H₁₁Br₂NO 
• 457948-80-0 C₁₆H₁₃NO 
• 111470-98-5 3-ethyl-8-hydroxyquinoline 
• 75457-13-5 8-hydroxy-3-methylquinoline 
• 826-81-3 2-methyl-8-quinolinol 
• 15599-52-7 5,7-dibromo-2-methylquinolin-8-ol 

Relevant articles and documents

A Phytochemical-Halogenated Quinoline Combination Therapy Strategy for the Treatment of Pathogenic Bacteria

With the continued rise of drug-resistant bacterial infections coupled with the current discouraging state of the antibiotic pipeline, the need for new antibacterial agents that operate through unique mechanisms compared with conventional antibiotics and work in synergy with other agents is at an all-time high. We have discovered that gallic acid, a plant-derived phytochemical, dramatically potentiates the antibacterial activities of several halogenated quinolines (up to 11 800-fold potentiation against Staphylococcus aureus) against pathogenic bacteria, including drug-resistant clinical isolates. S. aureus demonstrated the highest sensitivity towards gallic acid-halogenated quinoline combinations, including one halogenated quinoline that demonstrated potentiation of biofilm eradication activity against a methicillin-resistant S. aureus (MRSA) clinical isolate. During our studies, we also demonstrated that these halogenated quionlines operate through an interesting metal(II) cation-dependent mechanism and display promising mammalian cytotoxicity.

COMBINATION THERAPY FOR TREATING INFECTIONS DISEASES

The present invention provides compositions comprising a quinoline, a potentiating agent, and optionally a pharmaceutically acceptable carrier, for treating and/or preventing infectious diseases. The provided compositions may also include another therapeutic agent (e.g., antibiotic). The provided compositions may be useful in treating and/or preventing bacterial infections as well as inhibiting and eradicating biofilm formation.